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 Chemotherapy, radiation therapy, and targeted biological therapies are cancer treatments 
that can increase survivorship in patients with breast cancer, yet the associated cognitive side 
effects of therapy can significantly reduce quality of life (QOL). Cognitive Impairment has been 
identified by oncology nurses and patient’s as one of the most difficult symptoms to manage. 
However, methods to detect cognitive impairment are inconsistent in the literature.  
The purpose of this study was to examine the effect of cancer treatment on cognitive 
impairment in women with breast cancer using self-reported instruments. A descriptive, 
correlational pilot study was used to compare healthy women of similar age and those women 
who receive surgery, radiation, and chemotherapy for breast cancer at six months or less of 
endocrine therapy.  
This study evaluated three-self reported tools on cognition (attention, memory, and 
executive function) in conjunction with self-reported tools on symptom burden, QOL, anxiety, 
and depression. Results showed a significant difference between groups in attention and 
executive function but not in memory. Women with breast cancer reported significantly more 
symptoms and demonstrated more anxiety and depression than the healthy women. The findings 
 
 
of this study corresponded with findings from previous studies. However, a larger scale study 
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CHAPTER 1:  COGNITIVE IMPAIRMENT IN PATIENTS WITH BREAST CANCER 
 
Advancement in treatments and early detection of breast cancer have contributed to the 
increase in breast cancer survivors. Chemotherapy, radiation therapy, and targeted biological 
therapies are cancer treatments that can increase survivorship in patients with breast cancer, yet 
the associated cognitive side effects of therapy can significantly reduce quality of life (QOL) 
(Allen, D.H., Myers, J.S., Jansen, C.E., Merriam, J.D., & Von Ah, D, 2018; Ahles, Root & 
Ryan, 2012; Janelsins, Kesler, Ahles, & Morrow, 2014). Breast cancer survivors experience 
long-term cognitive effects that hinder their ability to return to work, function in social settings 
and perform everyday tasks post-chemotherapy treatment (Dwek et al., 2015; Wefel et al., 
2004). The symptoms of cognitive impairment can range from forgetfulness to the inability to 
focus when performing everyday tasks (Hess & Insel, 2007). Therefore, the need to understand 
the long-term cognitive side effects associated with cancer treatments and how they affect the 
QOL in patients with breast cancer is warranted. 
The National Cancer Institute predicts that the total number of cancer survivors will rise 
to more than 18 million by 2020, strengthening the need to address the long-term effects of 
chemotherapy treatment to improve the QOL of cancer survivors. The 5-year survival rate of 
breast cancer patients with Stage I-III has an estimated rate from 72-100%, while Stage 4 is 
significantly lower at 22% (American Cancer Society, 2020c). With the increasing number of 
breast cancer survivors, it is important to determine how cognitive impairment impacts 
survivors’ everyday lives (Allen et al., 2018; Ahles, 2013; Merriman, J. D., Aouizerat, B. E., 
Langford, D. J., Cooper, B. A., Baggott, C. R., et al., 2014; Vitali et al., 2017).  
Cancer survivors’ reports of cognitive impairment during and following chemotherapy 




(CRCI) by health care professionals.  Cognitive impairment has been identified by oncology 
nurses and patients as one of the most difficult symptoms to manage (Cox, A., Arber, A., 
Gallagher, A., MacKenzie, M., & Ream, E., 2017).  Although the occurrence of cognitive 
impairment has been documented with patients who undergo chemotherapy treatment (National 
Cancer Institute, 2016), little is known about the potential mechanisms that cause CRCI. In a 
systematic literature review, Hess and Insel (2007) found that all subjects in these breast cancer 
studies showed declines in various cognitive domains, whereas subjects in ovarian cancer 
studies did not show cognitive declines. The inconsistencies in these findings could be related 
to variety of cognitive measures (e.g., self-report instruments versus objective instruments) 
used, lack of demonstrated instrument validity and reliability and differences in chemotherapy 
treatment regimens. 
A challenge for researchers studying chemotherapy related cognitive functional is lack 
of a consistent definition the phenomenon. Definitions of cognitive function in the literature are 
nonspecific and generally refer to brain function (Allen, D.H., Myers, J.S., Jansen, C.E., 
Merriam, J.D., & Von Ah, D, 2018; Halligan, Kischka & Marshall, 2003; Jansen, 2005; 
Meyers, 2009; Myers, Wick, & Kelpm, 2015). Hess and Insel (2007) developed their 
conceptual model of CRCI by looking at changes in cognition due to the administration of 
chemotherapy. Hess and Insel (2007) defined cognitive function as “an individual’s higher-
order mental processes, may be altered among individuals diagnosed with cancer among two 
distinct and interacting pathways: (a) cancer diagnosis (meaning of cancer), leading to anxiety, 
stress, distress, and depression; and (b) direct physiological effects of cancer treatments, both of 
which may affect cognitive function” (p. 990). These mental processes include attention and 




memory, executive function; intellectual function; mood, thought content, personality, and 
behavior. Any mental process or processes could be affected, but most patients who receive 
chemotherapy report changes in attention, memory, and executive function (Jansen, 2005).  
Once one area of cognition is affected, eventually other domains could be affected (Halligan, 
Kischka & Marshall, 2003; Jansen, 2005).  
Another challenge for researchers is the wide variety of terms used within the literature 
to describe changes in cognitive function experienced by cancer patients.  These include: 
"chemo fog", "chemobrain", "chemotherapy-induced cognitive decline", "chemotherapy-
induced cognitive changes", "chemotherapy-associated cognitive changes", "cancer-related 
cognitive impairment", "chemotherapy-induced cognitive disruption", "cancer-related treatment 
symptoms," "cancer chemotherapy-related symptoms", and "chemotherapy-related cognitive 
impairment" (Ahles et al., 2002; Bender et al., 2006; Hurria et al., 2006; Johns et al., 2016; 
Meyers, 2009; Myers, Wick, & Kelpm, 2015; van Dam et al., 1998; Vitali et al., 2017). All 
these terms describe changes in cognition attributed to chemotherapy. It remains unclear which 
cognitive domains are most effected by the administration of chemotherapy.   
 While, cognitive impairment is attributed to chemotherapy, Myers, Wick, & Kelpm 
(2015) reported that cognitive complaints are present in some patients with breast cancer before 
receiving chemotherapy treatment and those cognitive complaints increased during treatment. 
The cognitive impairment experienced by cancer patient is a complex phenomenon with 
multiple contributing factors.  These contributing factors include predisposing factors (such as 
advanced age and genetics, physiological (such as types of treatment, combination of 
treatments) and psychological (such as depression and anxiety) (Hess and Insel, 2007).   The 




2009) to explain influencing factors that contribute to cognitive impairment in patients with 
breast cancer in conjunction with six self-report measures for cognition, symptoms burden, 
QOL, anxiety, and depression. 
Background/Significance 
 
Chemotherapy related cognitive impairment (CRCI) has been associated specifically 
with the areas of attention, memory, and executive function. If left untreated, CRCI may 
negatively affect QOL (Ahles, 2012; Hess & Insel, 2007; Myers, Wick, & Kelpm, 2015; Von 
Ah D et al., 2013; Vitali et al., 2017). Studies have suggested that 15-75% of women with 
breast cancer experience CRCI (Ahles et al., 2002; Bender et al., 2006; Hurria et al., 2006; 
Johns et al., 2016; van Dam et al., 1998), with some women experiencing symptoms up to 20 
years’ post-treatment (Koppelmans, V., Breteler, M. M. B., Boogerd, W., Seynaeve, C., Gundy, 
C., & Schagen, S. B.,2012). However, it is unclear which assessment tools are most effective in 
assessing for cognitive impairment. Once cognitive impairment is diagnosed, then providers 
can develop and provide interventions to minimize cognitive impairment’s impact on QOL.   
This study focused on women with breast cancer for several reasons.  Breast cancer 
long-term survival rates have increased significantly in recent years with survival rates of 78% 
after 15 years (American Cancer Society, 2020a).  Second, reporting of cognitive impairment is 
common among breast cancer survivors (Ahles et al., 2002; Bender et al., 2006; Hurria et al., 
2006; Johns et al., 2016).  Third, researcher had access to a population of patients with breast 
cancer.  In the next section, the researcher describes breast cancer and its treatment and the 






Cancer is caused by mutations that alter the expression or products of individual genes, 
and these mutations arise in many different cell and tissue types. Breast cancer forms in the 
tissue of the breast. It can occur in the lining of the milk ducts, ductal carcinoma, or in the lobes 
of the breast, lobular carcinoma. If any of these two types of cancer spread to surrounding 
tissue, it is then called invasive breast cancer (American Cancer Society, 2020a).  
Staging of Breast Cancer 
 The stages of breast cancer identify the extent to which cancer cells have spread from 
the original tumor. The staging of breast cancer is determined by the American Joint 
Committee on Cancer (AJCC) TNM system, further explained in Appendix B. T identifies the 
size of the breast tumor and if it has grown into nearby areas, N identifies if the cancer has 
reached nearby lymph nodes and M identifies whether the cancer has metastasized. Once the 
TMN has been determined, the oncologist will determine the stage of cancer. After the 
diagnosis and staging have been completed, the patient will then be informed of the 
recommended treatment regimen 
Tumor Types of Breast Cancer 
 The tumor types of cancer are classified by three receptors: estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor (HER). When 
classifying tumors, these receptors can either be positive (+) or negative (-). ER+ and PR+ 
tumors have an increased risk of cancer cells growing because these tumors have receptors for 
estrogen and progesterone, which can fuel the growth of cancer. In addition to these 




receptors are negative or positive. Based on the classification of the tumor cell, a treatment 
regimen will be identified.  
Treatment Types of Breast Cancer 
 After surgery to remove the breast cancer cells, chemotherapy may be recommended if 
the cancer is 1) invasive and the patient is premenopausal 2) in the lymph nodes or distant 
metastases are present (regardless of menopausal status) 3) HER+ or 4) cancer is triple negative 
(ER-, PR-, HER-). Chemotherapy is not recommended in noninvasive cancers that have little 
risk of spreading to other parts of the body. Once these two types of treatment are complete, 
endocrine therapy (ET) is initiated for ER+ and PR+ cancer cells.  
ET can include tamoxifen and aromatase inhibitors (AIs) (letrozole, anastrozole, and 
exemestane). Most premenopausal patients receiving AIs for a minimum of 5 years. Due to the 
broad range of cancer types and the range of treatments, predicting the influencing factors 
affecting cognition can be difficult. 
Hormone therapy in patients with breast cancer has been shown to induce menopause in 
premenopausal patients and worsen symptoms for women who are menopausal (Kilickap et al., 
2013). Menopausal-like symptoms include hot flashes, night sweats, vaginal dryness, and 
gradual changes in cognition. Patients treated with tamoxifen often report issues with hot 
flashes, vaginal discharge, and fatigue, whereas patients treated with AI report problems with 
arthritis, osteopenia, osteoporosis, and hyperlipidemia (Kilickap et al., 2013). Whether or not 
hormone therapy affects cognitive function is still to be determined. Gallicchio, Calhoun, & 
Helzlsouer (2017) conducted a prospective cohort study comparing cognitive function of 146 
women with breast cancer to 200 postmenopausal women without a history of cancer. This 




symptoms of numbness or tingling in extremities, fatigue, hair loss, forgetfulness, and difficulty 
concentrating than healthy controls.  Given the different symptoms associated with each type of 
hormone therapy, further evaluation is needed to determine which symptoms cause the most 
burden in breast cancer survivors.  
CRCI in patients with breast cancer can cause impairments in attention, memory, and 
executive function but we do not know if chemotherapy is the defining factor or if it is the 
combination of breast cancer treatment (radiation, ET, chemotherapy). To address this gap, this 
study will compare changes in self-reported cognitive impairment by evaluating two groups 
(heathy controls versus breast cancer patients who have had surgery, radiation, and 
chemotherapy) at six months or less of endocrine therapy. By assessing these two groups, we 
can evaluate the effects chemotherapy has on a patient's cognitive status. This study will 
explore the differences in cognition between patients with breast cancer who receive 
chemotherapy in conjunction with radiation and ET and healthy controls.  This study will also 
explore how self-report of cognitive impairment affects QOL. 
Conceptual Framework 
 
Myers (2009) developed a revised conceptual model of Chemotherapy-Related Changes 
in Cognitive Function by synthesizing the conceptual model of Chemotherapy-Related Change 
in Cognitive Function (Hess & Insel, 2007) and the revised Theory of Unpleasant Symptoms 
(TUS) (Lenz, Pugh, Milligan, Gift, & Suppe, 1997). The original TUS was created by Lenz et 
al. (1995) using three-factor categories (physiological, psychosocial and situational) that can 
vary in duration, intensity, quality, and distress that showed the relationships and experience of 
symptoms. This original TUS model was unidirectional and hypothesized that influencing 




(i.e., symptom clusters) the need for improving this model became apparent. In 1997, Lenz and 
colleagues revised the TUS to show a bi-directional flow. This revised model proposes that 
symptoms not only affect performance but in turn influence some physiological, psychological, 
and situational factors.  This model hypothesized that symptoms also contribute to changes in 
the physiological, psychological, and situation factors, and thus may increase or decrease 
symptom intensity. 
The conceptual model of Chemotherapy-Related Changes in Cognitive function was 
developed in 2007 by Hess and Insel through a systematic literature review focused on the 
experience of cognitive decline experienced by patients with cancer who received 
chemotherapy treatment. This model showed that cognitive function might be altered through 
two distinct and interactive pathways: the cancer diagnosis or the cancer treatment. The cancer 
diagnosis path leads to the development of anxiety, stress, distress, and depression. The second 
pathway illustrates a direct connection between the cancer treatment and the physiological 
effects. Both of these pathways interact with each other to explain which mediators and 
moderators may lead to changes in self-report cognitive function. These changes may affect 
QOL and functional ability for patients with cancer. 
Revised Conceptual Model of Chemotherapy-Related Changes in Cognitive Function  
 
The revised conceptual model of Chemotherapy-Related Changes in Cognitive Function 
provides "a more elaborate description and representation of the symptoms experience of 
cognitive impairment" (Myers, 2009, pg. E8) by combining the multiple symptom evaluations 
of the TUS with the antecedent components (cancer treatment and diagnosis) of the Conceptual 




antecedents in conjunction with multiple treatment symptoms that may be involved with 
increased cognitive impairment. By measuring these influencing factors, we can explore the 
relationships between symptoms, CRCI, and self-report of cognitive function in patients with 
breast cancer.  
The model describes two pathways for changes in cognitive function. The first pathway 
is through the cancer treatment which has different physiological factors (chemotherapy agents, 
radiation therapy, treatment dose and duration, concomitant medications, comorbidities, and 
low levels of vitamin D) that can contribute to associated toxicities (neurotoxicity, anemia, 
cytokines, low serum hormone levels, vascular injury) that in turn contribute to changes in 
cognitive function which can affect QOL and functional ability of patients with cancer. This 
pathway includes the timing, intensity, distress, and quality of concurrent symptoms (fatigue, 
pain, depression, and anxiety). These symptoms associated with physiological factors or 
toxicities of cancer treatment affect the QOL of patients with cancer.  
The second pathway proposes that when a person is diagnosed with a cancer diagnosis, 
their psychosocial state (stress, depression, anxiety, and distress) and situational state (lifestyle 
and personal experience) influences cognitive function. The two pathways interact to influence 
cognitive function and in turn affect the QOL and functional ability in patients with cancer. 
Another aspect of this revised conceptual model proposes that individual moderators 
(age, education, intelligence, genetic factors, and coexisting neurocognitive disorders) 
contribute to changes in cognitive function. The moderators can be applied to both pathways. 
The model, as a whole, provides researchers a framework to explain how chemotherapy can 
contribute to cognitive impairment experienced by patients with cancer through one or both 




Figure 1 The Revised Conceptual Model of Chemotherapy- Related Changes in 
Cognitive Function. 
 
The purpose of this study was to examine the effect of cancer treatment on cognitive 
impairment. This study examined the effects of cancer treatments on cognitive function in 
women following surgery, chemotherapy, and radiation and less than six months of endocrine 
therapy and compared their results to a sample of women without breast cancer. By assessing 
these two groups we examined the contribution chemotherapy may have on the development of 
cognitive impairment.  Based on the model above, we have adjusted the model to focus on the 





Figure 2 Adapted Revised Conceptual Model of Chemotherapy in Cognitive Function    
 
This study explored possible relationships breast cancer treatment and cognitive 
function. Concurrent symptoms, specifically depression, anxiety, pain, fatigue, and sleep 
disturbance were examined as potential influences or modifiers of cognitive function. The 
impact of cognitive function on QOL and functional ability were examined. Other potential 
moderators (age, education level and race) and situational factors (marital status, social support, 
diet and exercise, employment status) and physiological factors (comorbidities and menopause 
status) were examined in relationship to cognitive function.  
Study Purpose and Aims 
 
The purpose of this dissertation project was to: 1) Describe the differences between two 
groups (Group 1: Healthy controls vs. Group 2: Radiation, Chemotherapy, and ET (6 months or 
less) in self-reported attention, memory, and executive function 2)  Explore the association 
between symptom burden and QOL in breast cancer survivors 3) Examine relationship between 




treatment and dose, and comorbidities) situational factors (lifestyle and personal appearance) 
and cognitive function. 
In Chapter 2, relevant literature is described. In Chapter 3 the methodology, research 
design, and analysis plan is reported. In Chapter 4 the research results are reported.  Chapter 5 
concludes the dissertation with a discussion and implications of the findings. 
Definitions 
 
Chemotherapy-related cognitive impairment (CRCI) is defined as a change in cognition 
due to the administration of chemotherapy. Typical changes associated with CRCI are 
executive functioning, working memory, and inability to maintain attention. CRCI will be 
measured by the self-reported scores from the AFI, EMQ, and Neuro-QOL Cognitive Function 
Short Form. 
Attention is defined as “the taking possession by the mind, in clear and vivid form, of one of 
what seems simultaneous possible objects or trains of thought” (Macleod, 2006).  It will be 
measured by the Attentional Functional Index.  
Memory is defined as the power or process of reproducing or recalling what has been learned 
and retained especially through associative mechanisms (Merriam Webster, 2020). Memory 
will be measured by the revised Everyday Memory Questionnaire.  
Executive function is defined as a "higher-order cognitive processes, which include initiation, 
planning, hypothesis generation, cognitive flexibility, decision-making, regulation, judgment, 
feedback utilization, and self-perception” (Jansen et al., 2005, pg. 330). It will be measured by 




Symptom burden is defined as the collection of symptoms that may occur over the course of a 
patient's treatment. Symptom burden will be measured by the Memorial Symptom Assessment 
Scale Short Form (MSAS-SF).  
Quality of Life is defined as the overall well-being of an individual that may be affected by a 
person’s health (Hess and Insel, 2007). The QOL of patients with breast cancer will be assessed 
using the LASA. 
Anxiety and Depression will be assessed by the PROMIS Anxiety 6a and Depression 6a. 






CHAPTER 2: LITERATURE REVIEW 
 
  Cognitive impairment associated with cancer treatments, specifically chemotherapy is defined 
in the literature in multiple ways and referred to by numerous terms. With these varied 
definitions, multiple measures of cognitive impairment are used in the literature.  Thus, it is 
difficult for researchers to compare results and to determine the most appropriate cognitive 
impairment measurement tools for patients with cancer. Over the past decade as the number of 
cancer survivors has increased, the potential long-term effects of chemotherapy treatment, 
specifically on the brain and cognitive function became an area of interest for oncology 
researchers.   Women with breast cancer, who have been treated with chemotherapy, 
experience multiple symptoms that may or may not be associated with the development of 
cognitive impairment (Cheng, Wong, and Koh, 2016; Cutshall et al., 2015; Wagland et al., 
2015). Tumor type, treatment type and patient characteristics such as age, race, ethnicity, and 
education influence symptom burden and development of cognitive impairment. This study 
included patients who have received chemotherapy in conjunction with radiation and ET. This 
sample allowed the exploration of symptoms experienced, other physiological conditions, and 
situational factors in relationship to cognitive function. 
The purpose of this literature review is to describe cognitive impairment and how 
chemotherapy treatment may affect a patient’s CI. Further, this literature review describes 
measures of cognitive impairment used in previous studies. Included in the chapter are 
descriptions and research evidence that support the selected study instruments: self-report 
screening tools, symptom burden, cognitive function measures and QOL used in this study.  
This chapter begins with a review of cognitive impairment and CRCI. This review 




examination of self-report measures for CRCI, specifically addressing attention, memory, and 
executive function. Symptoms and symptom burden associated with breast cancer treatment 
(radiation, chemotherapy and ET) are discussed. Lastly, findings regarding the relationship 
between QOL and cognitive impairment are explored. 
Cognitive impairment Secondary to Chemotherapy 
 
Cognitive impairment in patients with cancer is a complex phenomenon that remains 
undertreated and under recognized. Cancer survivor’s complaints of problems with cognition 
during and following chemotherapy has led to increased recognition by medical professionals 
(Ahles, 2013; Merriman et al., 2013). The majority of studies conducted on CRCI report small 
sample sizes and limited power to detect subtle changes in cognitive function. Estimations of 
the incidence of cognitive impairment vary widely across studies ranging between 17% and 
35%. Ahles (2013) and Jansen et al., (2011) reported that 20-30% of patients experienced 
cognitive impairment prior to chemotherapy treatment while Ahles and Saykin (2001) found 
that 17-35% experience effects of cognitive impairment two or more years after the completion 
of chemotherapy treatment. It is unclear if the 65-70% of patients do not experience cognitive 
changes after chemotherapy treatment or if the assessment tools do not adequately capture the 
elements of cognitive impairment that are affected by chemotherapy.   
Qualitative studies. Several researchers have conducted qualitative studies with 
women who have received chemotherapy and reported cognitive impairment.  In a 
phenomenological study, Myers (2013) found that women (N=18) noticed cognitive changes 
prior to and after completion of chemotherapy treatment, with many subjects noticing these 
changes within the first one to two chemotherapy cycles. Von Ah, Habermann, Carpenter, and 




short and long term memory, the speed of processing, attention and concentration, language 
and executive function.  In a study of seven women, Kanaskie & Loeb (2015) found that some 
women began to experience cognitive changes during chemotherapy treatment, and some 
experienced these changes months after the completion of chemotherapy. The main cognitive 
difficulties noted in these samples included finding the right word, problems with memory, 
paying attention, concentration difficulties, organizing and prioritizing. All these identified 
areas fall into the three categories of cognitive impairment: attention, memory, and executive 
function.  
Quantitative studies of cognitive impairment associated with breast cancer. 
 
Van Dam et al. (1998) conducted the first quantitative study of women with high-risk breast 
cancer who had received high dose (n=34) or standard dose (n=36) of chemotherapy plus 
Tamoxifen and a control group (n=34) of women with breast cancer who did not receive 
chemotherapy. Each of the three groups were administered 13 neuropsychological tests which 
included: Rey Auditory Verbal Learning Test (RAVLT), Complex Figure test; Digit Span and 
Symbol of the Wechsler Adult Intelligence Scale (WAIS); Trailmaking A and B; D2 Test; and 
Stroop Test.  In addition to these neuropsychological tests each participant completed the 
Cognitive Problems in Daily Life Checklist which is a self-reported instrument that uses a 5-
point Likert scale to assess cognitive problems in memory, attention, thinking, and language. 
This study found that 32% of patients who received a high dose of chemotherapy, 17% of 
patients who received standard dose, and 9% of those who did not receive chemotherapy were 
cognitively impaired. No differences related to cognitive impairment and time since 




Wefel et al. (2004) assessed the effects of 5-fluorouracil, doxorubicin, and 
cyclophosphamide chemotherapy on cognition in 18 patients with breast cancer longitudinally. 
This study utilized neuropsychological tests which included the Arithmetic, Digital Span and 
Symbol WAIS; Trailmaking Test A and B; Verbal Selective Reminding Test (VSRT) 11 & 12. 
This study found that 66% of participants experienced a decline in cognitive performance over 
a six month period and 50% of those participants experienced a decline one-year later. The 
main domains of cognition impacted were attention, learning, and processing speed. Hurria et 
al. (2006) studied women with breast cancer before and six months after chemotherapy (n=28). 
This study found that 39% of the participants had worsened cognition over the six months. Out 
of the 39%, 25% (n=7) experienced a decline in cognitive function in two or more cognitive 
domains. The cognitive domains affected were visual memory, spatial function, psychomotor 
function, and attention.  
Using the Survivorship Survey neurocognitive questions about thinking, memory and 
attention, Buchanan et al. (2015) found that 60% of 2,296 breast cancer survivors, who were 
one-year post-treatment experienced issues with cognitive function.  Janelsins et al. (2011) also 
found that 75% of cancer survivors reported problems with attention, memory, or feelings of 
mental slowness during treatment and 35% experienced these changes in cognition up to a year 
post chemotherapy treatment. These studies suggest that the incidence of cognitive impairment 
is higher for breast cancer survivors who received chemotherapy. 
Terminology and Usage of CRCI  
 
 One of the biggest challenges in studying cognitive impairment related to 
chemotherapy or cancer treatment is lack of consensus on the definition of cognitive 




impairment, changes in cognition, cognitive fatigue, or any other of the various terms that 
examining cognitive impairment related to chemotherapy or cancer treatment (Craig et al., 
2013; Hislop, 2015; Moore, 2014). As a result, these various definitions influence 
measurement. Recent consensus among researchers is to use the term CRCI for patients with 
breast cancer who are receiving chemotherapy and experience cognitive impairment (Hess & 
Insel, 2007). However, there still is no consensus as to which domains of cognitive impairment 
should be the primary focus when evaluating CRCI. 
Researchers have used six domains to describe cognitive function which includes: 
attention/concentration, memory, executive function, psychomotor speed, processing speed, 
and language. Janelsins et al. (2011) conducted a systematic review and found that these four 
areas, executive function, memory, psychomotor speed, and attention are studied the most in 
patients with cancer who receive chemotherapy. More than 80 instruments have been used in 
assessing cognitive impairment in patients with cancer and each instrument influenced the 
findings, leading to the inconsistency of how researchers measure the different cognitive 
processes (Hess & Insel, 2007). The changes in cognitive function (CRCI) can be subtle, 
making detection difficult for health care professionals.  Because CRCI symptoms appear and 
disappear, using neuropsychological assessments only provides the researcher a snapshot in 
time, whereas when subjects self-report cognitive changes, the estimation if change over a 
period (Ganz et al., 2014).  
Neurocognitive tests are less likely to detect subtle cognitive changes than some self-
report measures (Schagen et al., 2002). Wefel et al. (2004) found that patients can score within 
reasonable limits on cognitive function even when they perceive they have a deficit in their 




breast cancer survivors self-reported cognitive complaints were not related to objective 
performance on neurocognitive tasks. As mentioned previously, CRCI has been associated 
specifically with the areas of attention, memory, and executive function.  
Self-Report Measurement Tools to Evaluate CRCI 
 
Self-report of a symptom is when a patient makes a statement about their sensation or 
perception of a disturbance in normal function that is caused by treatment or disease (Cleeland 
et al., 2010). These subjective responses lead to the development of patient-reported outcomes 
(PRO). In 2002, the National Institute of Health (NIH) reviewed the current state of knowledge 
and identified projects on how to help patients with cancer, identifying the need to refine and 
utilize symptom-report measures. However, NIH retired the program responsible for these 
efforts in 2013, without coming to a consensus about which self-reported assessment tools were 
best suited to research symptoms of patients with cancer (National Institute of Health, 2013).   
Hess and Insel (2007) found gaps in the literature about instruments used to measure 
cognitive function in the cancer population. These gaps identified that there is no current 
standard of measurement or assessment of cognitive function in patients with cancer. This 
review also found that self-reported and objective measurement tools were not correlated and 
the majority of the tools were not validated with the same patient populations. 
Inconsistencies in use of instruments to examine cognitive impairment are apparent in 
the literature. A meta-analysis by Jansen et al. (2007) showed that only 6 of the 13 identified 
neuropsychiatric tests were sensitive to chemotherapy-induced changes in patients with breast 
cancer.  The six tests were: 1) Fepsy finger tapping test 2) grooved pegboard for motor 
function; 3) Rey-Osterrieth Complex Figure Test (RCFT) copy, 4) Weschler Adult Intelligence 




Sensitivity Cognitive Scale (HSCS) for language; and 6) HSCS memory subset for verbal 
memory. None of the tests concerning attention/concentration, executive function, the speed of 
information processing, and verbal memory were sensitive to chemotherapy-induced changes. 
Hutchinson et al. (2012) found that 8 of 24 reviewed studies demonstrated a significant 
relationship between objective and patient-reported cognitive impairment. These studies 
assessed objective cognitive function using a variety of neuropsychological measures. Self-
reported cognitive impairment was significantly associated with performance on tests of 
memory in six studies. Significant relationships were also found in measures of attention, 
visuospatial performance, processing speed, and cognitive flexibility or executive function in 
individual studies when compared to subjective measures.  Out of all the domains of cognition, 
only visual and verbal memory were consistently found to be associated with subjective 
complaints. Due to the various types of cancer, treatment plans, psychosocial, and 
physiological factors experienced by patients, the inconsistencies and lack of a standard of 
measure will continue.  
Most studies use neuropsychology battery tests to assess cognitive impairment in 
patients with cancer who are undergoing chemotherapy treatment. For this pilot study, self-
report questionnaires were used, due to the length of time required to administrate the tests, 
required training for administration, high cost, and anticipated subject burden of 
neuropsychology battery tests (Lai et al., 2009; Loh et al., 2016). Because self-reported 
questionnaires are readily available and easy to administer, these tools have potential as  
clinical screening tools and then those with screened as likely cognitively impaired could be 




Three Areas that Define CRCI 
 
Attention 
Attention can be defined as "the taking possession by the mind, in clear and vivid form, 
of one of what seems simultaneous possible objects or trains of thought" (Macleod, 2006).  
Attention is the primary building block for cognitive function. Any deficit in attention can 
decrease a person's awareness or ability to perform tasks, making it hard to carry out everyday 
tasks or fulfill job requirements. 
Findings on how CRCI impacts attention are inconsistent. There are three neurological 
networks (alerting, orienting, and executive) that allow a normal attentional function (Cimprich 
et al., 2011). Most importantly, the executive network creates a coherent response from 
conflicting inputs derived from separate parts of the brain (Merriman et al., 2014).  While two 
studies found significant deficits in attention (Bender et al., 2013; van Dam et al., 1998) post 
chemotherapy, another study has found no gaps in attention (Wefel et al., 2004). Interestingly, 
Bender et al. (2013) found deficits in attention in patients with breast cancer prior to treatment 
when cognitive function was tested using a psychometrically sound test battery and scored by 
neuropsychology trained project nurses. Visovatti et al. (2016) assessed cognitive function in 
patients with colorectal cancer (CRC), precisely the domains of attention, memory, and 
cognitive control. They found that CRC patients had lower scores on the AFI compared to 
healthy controls, indicating that CRC patients perceive their effectiveness on everyday tasks 
that require attention and cognitive control as inadequate. 
In a repeated measures study with newly diagnosed breast cancer patients, Chen, 
Miaskowski, Liu, and Chen (2012) assessed these patients at multiple times starting from one 




Anxiety Inventory (STAI) State Anxiety Scale, Center for Epidemiological Study-Depression 
(CES-D), Lee Fatigue Scale (LSF), and the General Sleep Disturbance Scale (GSDS). Chen et. 
al. (2012) found that patients experienced lower scores for attention every month for eight 
months and then at ten months after surgery (n=200). Fifty-four percent had a decline in 
perceived attentional function one month after surgery, with 30-41% showing a continued 
decline one and two years later.  Initial attentional function scores were lower in the 
chemotherapy plus radiation group. Further results included statistically significant positive 
correlations of attention scores with anxiety, depression, fatigue, and sleep disturbance (p<.001) 
at each time point.  
Memory 
Memory is the power or process of reproducing or recalling what has been learned and 
retained especially through associative mechanisms (Merriam Webster, 2016). When 
researchers use neurocognitive tests or self-report tools, they refer to memory as either visual or 
verbal. Cognitive issues associated with memory can be found in patients with breast cancer. 
In 2005, Jansen et al. conducted a meta-analysis (n=16) to determine the impact 
chemotherapy has on each domain of cognitive functioning. This study found that visual 
memory was the one area with a small effect size and none of the other tests for attention or 
concentration, executive function, information processing speed, or verbal memory produced a 
significant effect size. Bender et al. (2006) conducted a repeated measure study on three 
different groups of patients with breast cancer. Group 1 only received chemotherapy (n=19); 
Group 2 received chemotherapy plus tamoxifen (n=15); Group 3 did not receive chemotherapy 
or tamoxifen (n=12). Group 1 and 2 had declines in verbal working memory, with Group 2 




Myers, Sousa, & Donovan (2010) conducted a secondary analysis which looked at 
patients with ovarian cancer and issues with memory. This study compared two groups: 1) 
received chemotherapy (n=638); 2) those who do not receive chemotherapy (n=68). Of the total 
sample of patients who received chemotherapy (n=638), 73% reported memory problems and 
had a higher mean score for self-reported memory problems than those who did not receive 
chemotherapy. These findings are supported by previous research that reports memory 
problems associated with chemotherapy (Ahles et al., 2002, Bender at al., 2006; Hurria et al., 
2006). This study also found a significantly negative correlation between memory and 
education level in patients who received chemotherapy (r =0.14, p<0.01). After controlling for 
education level and time since chemotherapy, four symptoms (fatigue, mood swings, 
neuropathy, and sleep disturbance) explained 37% of the variance for memory problems. 
Bender et al. (2013) found poorer verbal memory (p=0.05) in patients with breast cancer before 
treatment when compared to healthy controls, while Von Ah & Tallman (2015) found verbal 
memory to be significantly correlated with cognitive impairment in breast cancer survivors. 
Visovatti et al. (2016) assessed cognitive function in patients with colorectal cancer 
(CRC), precisely the domains of attention, memory, and cognitive control. They found no 
difference between groups (specify groups) using the self-report measure of memory, EMQ. 
The results from the EMQ was consistent with the Rey Auditory Verbal Learning Test 
(RAVLT) which is a neuropsychological test used to measure long-term, verbal memory (Van 
Dam et al., 1998). The study did indicate that older age, fewer years of education, and male 
gender had a significant association with lower long-term memory performance (p< 0.05) after 





Executive function refers to a "higher-order cognitive processes, which include 
initiation, planning, hypothesis generation, cognitive flexibility, decision-making, regulation, 
judgment, feedback utilization, and self-perception" (Jansen et al., 2005, pg. 330).  In the 
literature review by Jansen et al. (2005), quantitative studies identified that executive function 
could be affected in breast cancer survivors who received chemotherapy, along with memory, 
language, attention, and concentration. Pickens et al. (2010) conducted a systematic review of 
executive function measures, specifically for Alzheimer’s and Parkinson’s disease, and could 
not identify a standard of measure. Wefel & Schagen (2012) conducted a review of studies with 
breast cancer patients and found that most neuropsychological studies show a decline in 
executive function.   
Koppelmans et al. (2012) used the Stroop Color Word Test and Verbal Fluency 
neuropsychological tests to measure executive function. This study found that breast cancer 
survivors who received chemotherapy had a lower performance in executive function than 
women without a history of cancer. Von Ah & Tallman (2015) assessed executive function in 
breast cancer survivors using two neuropsychological tests: Trail Making Test B and 
Controlled Oral Word Association (COWA) and one self-reported questionnaire: the 
Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog). The self-report and 
neuropsychological results were significantly related (p<0.05). However, only the results from 
the FACT-Cog for executive function was significantly correlated with perceived cognitive 
impairment.  
 The PROMIS Neuro-QOL Cognitive Function Short form has been validated in 




executive function (HealthMeasures, 2020a).  This study will be one of the first to use this tool 
in breast cancer patients to accurately target potential issues with executive function. 
Symptom Burden 
 
Patients with breast cancer rarely experience only one symptom.  Wagland et al. (2015) 
conducted a scoping review to determine the treatment-related problems experienced by cancer 
patients and found 40 different outcome measurement instruments were used (n=51). Due to 
the different outcome measurement instruments, various definitions (n=98) were used to 
identify common symptoms. For example, cognitive problems had seven terms used to identify 
this symptom. Illustrating the importance of identifying common terms that identify common 
symptoms experienced by patients. This scoping review demonstrated that cancer patients who 
receive chemotherapy experience both physical and psychosocial symptoms. The top five 
symptoms according to prevalence were: nausea, vomiting, fatigue, cognitive problems, and 
depression. Hines et al. (2014) also reported that chemotherapy treatment may result in 
peripheral neuropathy, electrolyte imbalances, stress, fatigue, nausea/vomiting, pain, and 
medication side effects. 
Cutshall et al., (2015) surveyed cancer survivors (n=171) regarding symptom burden 
and found that the most bothersome symptoms included fear of re-occurrence, stress, fatigue, 
difficulty sleeping, weight gain, mental fogginess, pain, and neuropathy. A cross-sectional 
study by Cheng, Wong, and Koh (2016) evaluated symptom burden in women with breast 
cancer (n=222) using the Memorial Symptom Assessment Scale (MSAS) and found that 53% 
of respondents reported 1-5 symptoms, and 33% reporting 6-10 symptoms. The most 
commonly reported symptoms were lack of energy, peripheral neuropathy, pain, and difficulty 




the MSAS-SF (n=120) found that 92% felt a lack of energy and 69% had difficulty 
concentrating.  
A systematic review by Kirkova et al. (2006) found that the MSAS-SF was the most 
comprehensive questionnaire for both clinical and research assessments of symptom experience 
in patients with cancer.  By incorporating this scale, we can examine what symptoms emerge as 
cognition declines in patients with cancer who have been treated with chemotherapy.  The 
MSAS-SF is designed to evaluate the physiological and physical symptom burden in patients 
with cancer. The MSAS-SF is a valid and reliable measure of symptoms experienced in 
different types of cancer (Browall et al., 2013). The MSAS-SF measures 32 symptoms that may 
be expressed in patients with breast cancer. The revised conceptual model of Chemotherapy-
Related Change in Cognitive Function proposed that multiple symptoms (symptoms clusters) 
affect cognition. Also, psychological factors (anxiety and depression) are associated with of 
cognitive function and will be measured by the PROMIS Anxiety 6a and Depression 6a self-
report instrument. 
Anxiety and Depression 
According to the revised conceptual model of Chemotherapy-related changes in 
Cognitive function, multiple factors including anxiety and depression impact the development 
of cognitive impairment. Patients may experience anxiety or depression before, during or 
following cancer treatment. However, previously studies (Ahles et al., 2012; Jenkins et al., 
2006; Kanaskie, M., 2012; Myers et al., 2008; Saykin & Ahles, 2007; Schagen et al., 2014; van 
Dam et al., 1998) statistically controlled for pretreatment significant psychological distress and 
found that persistent cognitive changes post-chemotherapy occur irrespective of pretreatment 




showed a significant increase in risk of cognitive impairment among patients with no anxiety 
prior to treatment. Leading researchers to question how anxiety and depression contribute to the 
development of cognitive impairment.  
Higher levels of anxiety (p< 0.001) and depression (p< 0.001) has been associated with 
decreased cognitive function in patients with breast cancer (Chen et al., 2016; Chen, 
Miakowski, Liu, and Chen, 2012; Merriman et al., 2017; Miura, Ando, & Imani, 2016).  
Miakowski et al. (2006) measured depression with fatigue and found that patients with the 
highest reported levels of fatigue had the highest levels of depression. In another study by 
Kreukels et al. (2008) anxiety and depression were significantly correlated (p< 0.001) with 
fatigue in patients with breast cancer who received adjuvant chemotherapy. Webber and Davies 
(2011) study (n=120) found that 15% screened positive for anxiety and 25% screened positive 
for depression, with 6% screening positive for both. Deschields, Potter, Olsen, and Liu (2014) 
conducted a longitudinal study of patients with breast cancer (n=542) over a 12 month period 
and found that “feeling sad, worrying, and feeling irritable” were 3 out of the top 10 symptoms 
identified as most burdensome to patients.  
 To further evaluate this evidence, this study focused on psychological factors of 
depression and anxiety by administering the PROMIS Anxiety 6a and Depression 6a to our 
target population. In addition to these two psychological factors, we examined one groups of 
cancer patients to explore the relationship between symptoms and cancer treatment plan.  
Chemotherapy  
A study by Koppelmans et al. (2012) found that breast cancer survivors who received 
cyclophosphamide, methotrexate, and 5-fluorouracil had a lower performance in memory, 




average had a cognitive decline that correlated with a healthy control who was six years older. 
Jenkins et al. (2016) found that six months after chemotherapy treatment, patients with breast 
cancer reported fatigue, memory problems, and poorer QOL than those patients with breast 
cancer who did not receive chemotherapy. Wefel & Schagen (2012) found that the areas of 
cognition predominantly affected by chemotherapy were learning, memory, processing speed, 
and executive functioning. Ahles et al. (2010) also reported that patients with breast cancer 
treated with chemotherapy and those treated with ET both showed declines in cognitive 
function compared to healthy controls, suggesting that hormone therapy may also lead to CRCI. 
The study patients treated with both chemotherapy and ET had greater self-report of cognitive 
decline than those patients who just received chemotherapy. 
Endocrine Therapy 
Hormonal changes secondary to CRCI can affect the cognitive function of patients with 
breast cancer due to the depletion in estrogen. This oral anti-estrogen therapy is usually 
prescribed for five years for patients with breast cancer, and typical side effects include 
perceived changes in cognitive function, specifically in concentration and recall (Bender et al., 
2013). Patients with breast cancer who received aromatase inhibitors (AI) for six months were 
more likely to report symptoms of peripheral neuropathy, fatigue, difficulty concentrating, 
forgetfulness, and hair loss compared to women with no history of cancer who were also on AI 
therapy (Gallicchio, Calhoun, and Helzlsouer, 2017). These patients with breast cancer also 
reported a higher incidence of peripheral neuropathy and forgetfulness at one year of AI 
therapy.  
Miura, Ando, and Imai (2016) conducted a cross-sectional study with women with 




had more severe menopause and depressive symptoms. Kilickap et al. (2013) found that ET 
with either tamoxifen or AI did not affect cognitive function when compared to patients with 
breast cancer who did not receive ET. In addition to cognitive function, they also found similar 
scores in QOL. However, the majority of the patients in each group (>90%) had received 
chemotherapy, furthering the need for studies to look at the effects chemotherapy and ET may 
have on the development of cognitive impairment. 
Breckenridge et al. (2012) conducted a cross-sectional study of breast cancer patients 
three years into anti-estrogen therapy and found associations among ET therapy, poorer 
cognitive function, and worse mood. Ribi et al. (2012) found no change in self-reported 
cognitive function one year after completion of ET, leading researchers to question the actual 
effects ET has on cognition and if ET alone can cause cognitive changes. This study will 
compare two groups: group 1 will be healthy controls and group 2 will be women with breast 
cancer who have received radiation, chemotherapy, and six months or less of ET therapy. In 
addition to contributing psychological factors and symptoms that affect self-report cognitive 
impairment, QOL will be addressed in patients with breast cancer. 
Quality of Life  
 
Cancer treatments, including chemotherapy, radiation, and ET have led to the increase 
in number of breast cancer survivors; however, side effects associated with their administration 
can significantly reduce QOL. Issues with cognitive function are one of the most frequently 
reported symptoms of patients with breast cancer who have been treated with chemotherapy.  
Cognitive Impairment can substantially affect the QOL in breast cancer survivors (Myers, 




 Myers, Wick, & Kelpm (2015) reported that cognitive complaints are present in some 
patients with breast cancer before receiving chemotherapy treatment and those cognitive 
complaints increased during treatment.  In this study, subjects reported a negative rating for 
QOL within five years of receiving chemotherapy, however, those patients with breast cancer 
who completed chemotherapy more than five years previously did not differ in their QOL 
scores from healthy controls.  Miura, Ando, and Imai (2016) cross-sectional study of women 
with breast cancer (n=93) had 90.8% undergoing ET, and this majority had low QOL scores. 
The lower QOL scores were also associated with higher cognitive impairment and depression 
scores. Deschields, Potter, Olsen, and Liu (2014) measured QOL with the Functional 
Assessment of Cancer Therapy-General Scale (FACT-G) and found that overall QOL scores 
were stable over the 12-months.  This study also found that patients QOL scores were 
decreased as symptom burden increased, with 89-93% of patients (n=542) reporting at least one 
symptom. This study also showed the QOL correlated negatively with the total MSAS scores 
for each time point. These results were all significant (p<0.001) and found that patients with 
low QOL scores had higher reported symptom burden. 
Chen et al. (2016) conducted a secondary analysis of data from the previous study 
(Chen, Miaskowski, Liu, and Chen (2012) to examine QOL in breast cancer survivors two 
years after surgery (N=97). There were four groups in the study: Group A= low mean scores on 
all five symptoms; Group B= low scores on cognitive impairment and physical fatigue but 
moderate for sleep disturbance, anxiety, and depression; Group C= moderate levels on all five 
symptoms; Group D= highest mean scores on all five symptoms. Group A had the highest QOL 
scores and had a significantly better overall QOL than those in Group D (p=0.08). Illustrating 




This study measured QOL using the LASA since chemotherapy may increase symptom 
burden on patients with breast cancer, contributing to a change in self-report of cognitive 
function and QOL.  
Summary 
Further research is needed to identify patients which breast cancer are at an increased risk for 
declines in cognitive function due to the administration of chemotherapy. Subsequent studies 
are needed to identify intervention(s) to mitigate the impact of chemotherapy on cognitive 
function. First, we need to determine the best tools possible to detect these subtle changes in 
cognition and determine if chemotherapy is the determining factor for declines in self-reported 
cognitive function. In Chapter 3, the methodology of the study is discussed with a description 
of the psychometric properties of the seven self-report questionnaires used to measure cognitive 




CHAPTER 3:  RESEARCH DESIGN 
 
Cognitive impairment in breast cancer patients who receive chemotherapy has been 
shown to affect the cognitive domains of attention, memory, and executive function, so this 
study focused on these specific areas (Hess & Insel, 2007; Von Ah D et al., 2013; Myers, Wick, 
& Klemp, 2015).  Symptom burden (number of symptoms and distress level), QOL, and 
cognitive impairment (attention, memory, and executive function) have been found to be 
correlated, so this study explored which symptoms were experienced by this patient sample.  
These symptoms may or may not be associated with the type of cancer treatment 
(chemotherapy, radiation, and ET). This study included two groups: one breast cancer patient 
group who received surgery chemotherapy, radiation, and ET and a healthy control group. 
The purpose of this study was to examine the effect of cancer treatment on cognitive 
impairment. This pilot study compared cognitive function in 2 groups: 1) healthy control 
similar in age to group with breast cancer and 2) a breast cancer group following surgery, 
radiation, and chemotherapy and currently receiving ET for six months or less. By comparing 
these two groups, it was possible to evaluation the relative influence of chemotherapy on the 
cognitive function. 
This descriptive, correlational pilot study that compared healthy women of similar age 
and those women who receive surgery, radiation, and chemotherapy for breast cancer at six 
months or less of endocrine therapy. The measured variables included cognitive function 
(attention, memory, and executive function), symptom burden (anxiety, depression), symptoms 
measured by MSAS-SF, and QOL. Each participant was administered a demographic form, 
three cognitive impairment tools (AFI, EMQ, Neuro-QOL), LASA, MSAS-SF, PROMIS 






1. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer in executive function, 
memory, and attention? 
2. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and QOL? 
3. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and self-report of 
symptom burden, anxiety, and depression?  
4. Is there an association between QOL, anxiety, depression and symptom burden among 
women with breast cancer who have been on endocrine therapy for 6 months or less and 
women without breast cancer? 
Sampling methods/subjects 
 
This pilot study was a descriptive, correlational study that used a consecutive 
convenience sample to examine cognitive impairment with QOL and symptom burden at one 
time-point in the patient’s treatment plan (6 months or less on ET therapy). This pilot study was 
conducted at the Leo Jenkins Cancer Center, a cancer center associated with a tertiary medical 
center and university.  
In determining the sample size for this pilot study, Hetzog (2008) was used, providing 
evidence that 20 patients per group (n=40) would sufficiently assess the feasibility and 
acceptability of this study. Hertzog (2008) also states that finding an effect size for this sample 




effect size or provide a preliminary test of a research hypothesis is not appropriate (NCCIH, 
2017). 
The inclusion criteria for patients with breast cancer will include current patients with 
breast cancer, who have had surgery, chemotherapy and radiation, are on ET for 6 months or 
less, English speaking, female, all ethnic/racial groups, and < 18 years of age. Exclusion criteria 
1) any prior cancer diagnosis 2) Non-English-speaking patients. Inclusion criteria for healthy 
controls will be English speaking, female, all ethnic/racial groups, < 18 years of age. Exclusion 
criteria will be 1) any prior diagnosis of cancer 2) Non-English speaking.  
An employee of the Leo Jenkins Cancer Center identified potential participants for the 
study based on the inclusion and exclusion criteria. The PI approached all potential participants 
at the Leo Jenkins Cancer Center during their regularly scheduled clinic visit. The PI explained 
the study to the potential participant, using the informed consent IRB Human subjects 
approved. If the potential participants agree to participate, the PI enrolled the patient into the 
study by having the patient sign the informed consent and HIPPA form. The healthy controls 
were obtained by utilizing East Carolinas University email blast that utilized information about 
the study. All willing participants responded to the PI through email and a link to the survey in 
REDCAP was sent to the participant to complete.  All participants were asked to complete the 
seven questionnaires and demographic form AFI, EMQ, Neuro-QOL, MSAS-SF, LASA, 
PROMIS Anxiety 6a and Depression 6a).  
 
Methods/Data collection procedures 
 
The demographic form, AFI, EMQ, Neuro-QOL, MSAS-SF, LASA, PROMIS Anxiety 




complete. Demographic information collected included age, gender, race, ethnicity, education 
level, income, marital status, and smoking status. The PI abstracted from the patient's chart all 
remaining information not collected in the demographic form. The demographic and data 
abstracted from the chart will be stored on an ECU pirate drive under a secured and locked 
folder.  
Electronic Medical Record (EMR) Abstraction 
The electronic medical records (EMR) of 20 participants were accessed through the 
Vidant Medical Center (VMC) intranet. Utilizing the EMR, the PI abstracted demographic data 
and key contributing factors to the development of CRCI. An SPSS spreadsheet created by the 
PI served as the data collection tool and was stored on ECU pirate drive, a secure site. Only the 
PI had access to the data collection sheet once all data has been abstracted. Once a patient was 
recruited into the study, they were given a unique identification number, and only the PI had 
access to that list.  
All information was entered using the unique identification number. Information that 
was collected from the EMR after patient's permission is (a) height and weight; (b) type and 
stage of cancer; (c) laboratory values for hemoglobin, hematocrit, and c-reactive protein (CRP); 
(d) medication regimens that include type of medication and dose (chemotherapy medications, 
ET medications, anti-anxiety, anti-depression, pain, steroids, anti-inflammatory, sleep 
medications); (e) current/previous medical diagnosis; (f) location of radiation.  All data was de-
identified for statistical analysis. An SPSS spreadsheet was used for the data where the PI 
stored the participant's information. 
Self-Report Instruments 
 




The Attentional Functional Index (AFI, Cimprich, 1992) is a 16-item instrument that 
measures directed attention and accesses cognitive distress.  The design of the instrument 
allows measurement of perceived effectiveness in everyday activities that are identified through 
attention and working memory. The first 12 questions measure attentional function in the 
higher level of cognitive activities and the remaining four measure subjective experience of 
attentional difficulties; the last four are reversed scored. The scores on the AFI range from 0-10 
with lower scores indicating poorer levels of attentional function. The AFI has been validated 
with register nurse students (Sanders, C. M., Yankou, D., & Andrusyszyn, M., 2005) and 
various cancer patients, specifically breast, lung, and colorectal (Cimprich, Visovatti, & Ronis, 
2011; Chen et al., 2016 (Cronbach alpha= 0.95); Chen, Miaskowski, Liu, & Chen, 2012 
(Cronbach’s alpha= 0.95); Johns et al., 2016 (Cronbach’s alpha= 0.87); Myers, Wick, and 
Klemp, 2015 (Cronbach’s alpha=.89); Visovatti et al., 2016 (internal consistency coefficient= 
0.91). 
Everyday Memory Questionnaire 
The revised Everyday Memory Questionnaire (EMQ) measures the various everyday 
memory problems and consists of subjective, meta-memory reports that examine the objective 
level of performance (Sunderland et al., 1983). The revised EMQ is a 13-item scale that can 
range from 0 to 52.  Higher scores indicate more reported difficulties; each item is scored on a 
5-point rating scale (0 to 4), based on the frequency of the reported problem. This revised 13 
item EMQ is easy to use and screen objective memory impairment in patients in the clinical 
setting. The EMQ has been used and validated in adult populations (Efklides et al., 2002 
(Cronbach’s alpha= 0.89); Royle & Lincoln, 2008 (Cronbach’s alpha= 0.91)) and colorectal 




Neuro-QOL Cognitive Function Short Form 
The Neuro-QOL Measurement System has self-report instruments of health-related 
QOL for adults and children which are available as adaptive computer tests (CAT) or fixed 
length short form tests. Neuro-QOL psychometricians calibrated each item bank using item 
response theory (IRT). Per the standardized Neuro-QOL manual, the T-score (mean of 50, SD 
of 10) for this form is 36.4 with a standard error of 5.2. The 95% CI is 26.2 to 46.6. To evaluate 
executive function, we will use the Neuro-QOL Cognitive Function Short Form. The Neuro-
QOL Cognitive Function short form is an 8-item Likert scale that ranges from 1-5 (1=very 
often to 5= never). The scores can range from 8-40 with higher scores indicating a decrease in 
executive functioning. The Neuro-QOL Cognitive Function short form was chosen based on the 
recommendations from NIH to have researchers use the same measurement tools when 
assessing specific patient-reported outcomes.  
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) 
The Memorial Symptom Assessment Scale-Short Form (MSAS-SF) is used to evaluate 
the physical and psychological symptom burden in patients with cancer. The MSAS-SF is a 
self-report instrument that allows patients to rate symptom distress associated with 28 physical 
and four psychological symptoms. MSAS-SF subscales include the global distress index (GDI) 
(4 psychological symptoms: feeling sad, worrying, feeling irritable, and feeling nervous, and 
six physical symptoms: lack of energy, pain, lack of appetite, feeling drowsy, constipation, dry 
mouth, numbness or tingling). The physical symptom distress score (PHYS) comprises 12 
prevalent physical symptoms (pain, lack of energy, lack of appetite, feeling drowsy, 




dizziness) The six prevalent psychological symptoms (worrying, feeling sad, feeling nervous, 
difficulty sleeping, feeling irritable, and difficulty concentrating). 
The frequency of all symptoms is over a seven-day period or within the past week. Each 
physical symptom is scored on a 5-point Likert scale (0.8=not at all; 1.6=a little bit; 2.4= 
somewhat; 3.2= quite a bit; 4= very much).  Each psychological symptom is scored from 1-4 
(1= rarely; 2= occasionally; 3=frequently; 4= almost constantly). Scores range from 0-104, with 
higher scores indicating a higher symptom burden. The Cronbach alpha coefficient for the 
MSAS ranges from 0.76-0.87 (Protenoy et al., 1994).  The MSAS-SF has been validated in 
patients with cancer in numerous studies (Browall et al., 2013; Cheng, Wong, and Koh, 2016 
(Cronbach’s alpha from 0.72 to 0.78); Deschields, Potter, Olsen, and Liu, 2014 (alpha 
reliability score= 0.90); Kirkova et al., 2006; Webber & Davies, 2011) 
Linear Analogue System Assessment (LASA) 
 The LASA scale is used to measure quality of life by using single-item assessments. 
This instrument asked to describe a person’s overall quality of life during the past week. It is a 
10 point Likert scale that can range from 0-10 (0= as bad as it can be to 10= as good as it can 
be), with higher scores indicating a higher quality of life.  The purpose of the LASA is to have 
each item standalone so there is no total score. Without a total score, no statistical verification 
for internal consistency or Cronbach’s alpha is obtained.  
PROMIS Anxiety 6a and Depression 6a 
 Both PROMIS tools for anxiety and depression are a 6-item scale rated on a 5 point 
Likert scale (ranging from 1=never to 5=always). They both are self-report instruments that ask 
the patient to recall how they felt in the past 7 days. Both can range from 6-30, with higher 




recommendations from NIH to standardize the use of specific measurement instruments that 
will be used in all research studies.  
Data Analysis  
 
All statistical analysis was analyzed through Statistical Package for the Social Sciences 
(SPSS), version 26. Preliminary analysis was conducted to confirm there was no violation of 
the normality, linearity and homoscedasticity assumptions for the correlation analysis.  
Research Question 1: What is the difference between women with breast cancer who have 
been on endocrine therapy for 6 months or less and women without breast cancer in 
executive function, memory, and attention? 
T-Tests were used to compare cognitive impairment for each test (AFI, EMQ, and Neuro-QOL) 
by comparing Group 1 and Group 2. Pearson product-moment correlation coefficients were 
used to examine the relationship between cognitive impairment and cancer treatment.  
Research Question 2: What is the difference between women with breast cancer who have 
been on endocrine therapy for 6 months or less and women without breast cancer and 
QOL? 
T-Tests were used to compare QOL scores of the two groups. Pearson product-moment 
correlation coefficients were used to examine the relationship between QOL and cancer 
treatment.  
Research Question 3: What is the difference between women with breast cancer who have 
been on endocrine therapy for 6 months or less and women without breast cancer and 




T-Tests were used to compare symptom burden scores of the two groups. Pearson product-
moment correlation coefficients were used to examine the relationship between symptom 
burden and cancer treatment.  
Research Question 4: Is there an association between QOL, anxiety, depression and 
symptom burden among women with breast cancer who have been on endocrine therapy 
for 6 months or less and women without breast cancer? 
Pearson product-moment correlation coefficients were used to examine the relationship 
between QOL (LASA) and symptom burden (MSAS-SF, PROMIS Anxiety 6a, and Depression 




CHAPTER 4:  RESULTS 
 
This chapter reports the findings from a descriptive, correlational pilot study of cognitive 
function of 20 women with breast cancer who received chemotherapy treatment and a 
comparison group of 20 healthy women. The healthy women answered an electronic survey 
through REDCAP while the women with breast cancer completed the survey instruments 
during a clinical visit to the Leo Jenkins Cancer Center. The purpose of this study was to 
examine the effect of cancer treatment on cognitive impairment, while investigating other 
potential symptoms through the different survey instruments. The following research questions 
were asked: 
1. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer in executive function, 
memory, and attention? 
2. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and QOL? 
3. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and self-report of 
symptom burden, anxiety, and depression?  
4. Is there an association between QOL, anxiety, depression and symptom burden among 
women with breast cancer who have been on endocrine therapy for 6 months or less and 
women without breast cancer? 
All statistical analysis was analyzed through Statistical Package for the Social Sciences 
(SPSS), version 26. Preliminary analysis was conducted to confirm there was no violation 




This chapter describes the characteristics of the sample, followed by the findings for each of 
the four research questions.   
Sample Characteristics 
 
A total of 40 participants were enrolled in this study, 20 healthy controls and 20 breast cancer 
patients. Demographic characteristics are shown in Table 1. Seventy percent of the healthy 
control group were between the ages of 50 and 69 while 75% of breast cancer group were 
between ages of 50 and 69. Fifty percent of participants were married in both groups, however 
25% of the breast cancer group were single while only 10% of healthy controls were single. 
The main differences between the groups were in education and ethnicity; 75% of breast cancer 
survivors were black and only 30% of healthy controls were black. The healthy controls were 
more likely to have earned a college degree or higher (65%) compared to 30% of the breast 





Research Question 1.  Comparison of Control and Breast Cancer Survivors’ Cognitive 
Function: Attention (AFI), Executive Control (Neuro-QOL) and Memory (EMQ). 
An independent samples t-test was conducted to compare the attention, executive function, and 
memory scores between the healthy control and breast cancer patients’ groups.  There were 
significant differences between control and patient groups in attention (AFI) with moderate 
effect size (η2 =.104). In addition, there were significant differences between control and patient 




significant differences (p >.05) between control and patient groups in memory (EMQ) as seen 
in Table 2.  
 
Question 2: Comparison of Control and Breast Cancer Survivors’ Quality of Life (QOL) 
An independent samples t-test was conducted to compare the QOL scores between the healthy 
control (M=8.25, SD=1.29) and breast cancer patients (M=7.40, SD=2.46) groups. While breast 
cancer patients reported a lower QOL (global quality of life), this difference between groups 




Question 3: Comparison between groups on symptom burden, anxiety and depression 
Symptom burden: An independent samples t-test was conducted to compare the total 
symptom burden scores between the healthy control group (M=.30, SD=.29) and breast cancer 
patients (M=1.02, SD=.75) groups.  Breast cancer patients reported significantly more 
symptoms as shown in Table 3. The most prevalent symptoms reported by the breast cancer 
patients were lack of energy (40%) and difficulty sleeping (35%).  For the healthy controls, the 
most prevalent symptoms were difficulty sleeping (15%) and worrying (15%) and there were 
few other symptoms reported.  Also noted in Table 2 is the difference between the physical 
symptoms, psychological symptoms, and global distress between the two groups. The breast 
cancer patients had a mean score that was either double or triple in comparison to the healthy 





Anxiety and Depression 
 
An independent samples t-test was conducted to compare the anxiety scores between the 
healthy control (M=1.34, SD=.52) and breast cancer patients (M=2.16, SD=.96) groups.  Breast 
cancer patients demonstrated significantly more anxiety than healthy controls (p=.002) and the 
effect was large (η2=.228).  An independent samples t-test was conducted to compare the 




(M=1.77, SD=.77) groups.  Breast cancer patients in this sample were significantly more 
depressed than healthy controls (p=.01) and the effect size was large (η2=.161).  
Question 4: Association between QOL, anxiety, depression, and Symptom burden: 
Pearson product-moment correlation coefficients were used to examine the relationship 
between QOL (LASA) and symptom burden (MSAS-SF, PROMIS Anxiety 6a, and Depression 
6a) in the two groups shown in Table 4 and Table 5. For the healthy controls there was a strong 
negative relationship between QOL and depression (r =-.62), with higher quality of life 
associated with lower levels of depression. For the breast cancer patients there was a strong 
negative relationship between QOL and anxiety (r = -.59), depression (r = -.62), physical 
symptom subscale (r = -.50), psychological subscale (r = -.56), global distress index (r = -.56), 
and total symptom burden (r = -.61). These correlations demonstrate that higher quality of life 




Pearson Product-moment Correlations Between Measure of Quality of Life and Symptom 
Burden for Healthy Controls 
 
 
Measure                       1               2               3               4               5               6               7 
1. Overall Quality of Life       - 
2. Anxiety    -.45                -               
3. Depression    -.62**        .72***          -          
4. Physical Symptom Subscale     -.48       .11             .37      -   
5. Psychological Subscale              -.30       .56*           .68***       .51                  - 
6. Global distress Index                 -.38             .43             .65**         .75***        .92***       - 
7. Total Symptom Burden  -.33       .41             .59**         .79***        .87***    .95 ***         - 









Pearson Product-moment Correlations Between Measure of Quality of Life and Symptom 
Burden for Breast Cancer Patients 
 
 
Measure                       1               2               3               4               5               6               7 
 
1. Overall Quality of Life       - 
2. Anxiety    -.59*             -               
3. Depression    -.62**       .57*                -          
4. Physical Symptom Subscale     -.50*       .74***        .59*     -   
5. Psychological Subscale              -.56*       .77***        .64**      .77***         - 
6. Global distress Index                 -.56*           .81***       .60**      .99***      .90***        - 
7. Total Symptom Burden  -.61**       .78***        .64**      .95***     .86***     .95***        - 
* p <.05, ** p < .01, ***p <.001 
Summary 
 
The results from the statistical analysis showed that attention (AFI) and executive function 
(Neuro-QOL) were significantly different between the two groups. However, the two groups 
were not significantly different in memory (EMQ). The women with breast cancer group also 
reported more symptoms than the healthy control group, with both reporting difficulty sleeping 
as one of the top symptoms they experienced during the past week. One of the main symptoms 
expressed by the women with breast cancer, lack of energy, was not reported by any in the 
healthy control group. For both groups a higher QOL (LASA) was associated with a lower 
level of depression. However, women with breast cancer reported higher depression and 
anxiety scores. The results from this sample found that women with breast cancer differ from 
women without breast cancer of a similar age different in two dimensions of cognitive function 





CHAPTER 5:  CONCLUSION 
 
 This chapter will discuss the descriptive, correlational pilot study conducted with 20 
women with breast cancer and 20 healthy women to evaluate cognitive function, quality of life 
(QOL), and symptom burden. The purpose of this study was to examine the effect of cancer 
treatment on cognitive impairment. This pilot study compared cognitive function in 2 groups: 
1) healthy control similar in age to group with breast cancer and 2) a breast cancer group 
following surgery, radiation, and chemotherapy and currently receiving endocrine therapy (ET) 
for six months or less. By comparing these two groups, it was possible to evaluate the relative 
influence of chemotherapy on the cognitive function. 
This descriptive, correlational pilot study compared healthy women of similar age and 
those women who receive surgery, radiation, and chemotherapy for breast cancer at six months 
or less of endocrine therapy. The measured variables included cognitive function (attention, 
memory, and executive function), symptom burden (anxiety, depression), symptoms measured 
by MSAS-SF, and QOL. For the women with breast cancer, a demographic form, three 
cognitive impairment tools (AFI, EMQ, Neuro-QOL), PROMIS Anxiety 6a and Depression 6a, 
MSAS-SF, and LASA were administered at one clinic appointment at the cancer center. The 
healthy control group was sent an electronic survey with the seven instrument tools and 
demographic form through REDCAP. All information for both groups was imported into SPSS 
for statistical analysis to answer the following research questions: 
1. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer in executive function, 




2. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and QOL? 
3. What is the difference between women with breast cancer who have been on endocrine 
therapy for 6 months or less and women without breast cancer and self-report of 
symptom burden, anxiety, and depression?  
4. Is there an association between QOL, anxiety, depression and symptom burden among 
women with breast cancer who have been on endocrine therapy for 6 months or less and 
women without breast cancer? 
Discussion of Findings 
 
This study utilized the Revised Conceptual Model of Chemotherapy-Related Changes in 
Cognitive Function by Hess and Insel (2007) to evaluate the effects of chemotherapy treatments 
on cognitive function as well as other factors such as demographic characteristics, QOL, 
anxiety, depression, and symptom burden. The two groups were similar in age but had major 
differences in ethnicity and education status. Most previous studies have included primarily 
white women with breast cancer. This study differed in that the sample of breast cancer patients 
was predominantly black, however, the sample size was small and as a result insufficient for 
comparison by ethnicity and education level.  
The healthy control group had 65% with a college degree or higher while the women 
with breast cancer only had 30%. The healthy control group was acquired through the ECU list 
server email. This email went to faculty and staff of ECU, with majority of the participants 
having a bachelor’s degree or higher, which is required for their job.  According to the United 
States Census, 30.5% of the population in North Carolina has a college degree or higher while 




Bureau, 2019). This study’s healthy control group had a significantly higher educational level 
compared to North Carolina and Pitt County statistics. The women with breast cancer had a 
lower educational level compared to the healthy control but was comparable to North Carolina 
and Pitt County statistics. Issues with lower educational status can have an impact on CI 
according to previous studies (Myers, Sousa, & Donovan, 2010; Visovatti et al., 2016) and thus 
may be a consideration in interpretation of the results. It is possible the differences in cognitive 
function between the healthy control group and the women with breast cancer can be partially 
explained by the difference in education levels between groups. 
The women with breast cancer all had chemotherapy, radiation and six months or less of 
endocrine therapy. Women in this study received a variety of chemotherapy agents, thus with 
this limited sample size, no statistical analysis could be conducted for the variations in 
chemotherapy drugs, dosage, or duration of treatment and chemotherapy regimens’ possible 
effects on cognitive function. The women with breast cancer did show significant differences in 
attention (AFI) and executive function (Neuro-QOL) when compared to healthy control group. 
Memory (EMQ) was not significantly different between groups, which contradicts with 
previous findings of similar studies that used neuropsychological battery tests (Bender at al., 
2006; Hurria et al., 2006).  
 Reasons for the differences in results from previous studies that contradict our findings 
could be contributed by the difference in tools administered, subject demographics and study 
design. Bender et al. (2006) used the following neuropsychological tests: the Digital Vigilance 
Test, Trail-Making test-B, Rey Auditory Verbal Learning Test (RAVLT) and Rey Complex 
Figure Test (RCF). Then compared these tests to the participants self-reported cognitive 




deteriorated over time on both the neuropsychological tests and self-reported questionnaire. 
Hurria et al. (2006) assessed attention, memory, and executive function through several 
neuropsychological tests. The results of the test showed a decline in cognitive function from 
before to 6 months after chemotherapy, with the most affected areas being memory and 
attention.  
In another study, Johns et al. (2016) compared neuropsychological tests (Stroop Test) 
and self-reported questionnaires (AFI) on attention to evaluate the effectiveness of a 
mindfulness-based stress reduction class on breast and colorectal cancer patients. The results 
showed an improvement in the scores using the AFI questionnaire, but no differences were 
show with the Stroop Test. Visovatti et al. (2016) assessed cognitive function in patients with 
colorectal cancer (CRC), precisely the domains of attention, memory, and cognitive control. 
This study compared neuropsychological tests (Attention Network Test (ANT), digital span 
(DS) test, Rey Auditory Verbal Learning Test (RAVLT)) and self-reported questionnaires (AFI 
and EMQ) for attention and memory. The results for the neuropsychological tests showed that 
for attention, the CRC group had slower response times and reported lower scores on the AFI. 
The EMQ and RAVLT results showed no significance differences between groups.  
Jansen et al. (2007) conducted a meta-analysis of the sensitivity of various 
neuropsychological tests used to detect CRCI. There review of 13 studies showed 29 different 
neuropsychological tests, but no clear indication on why these tests were chosen. All tests for 
executive function, attention, and concentration did not show a significant effect size. While 
only one test showed a significant effect size for memory. Hess and Insel (2007) review of the 
literature also noted that there were no correlations between self-reported cognitive changes 




tools that were utilized when assessing attention, memory, and executive function. Majority of 
the tools used to assess these areas of cognition were neuropsychological tests and these tests 
can be expensive for the patients. Hence the need for further research on self-reported cognitive 
impairment tools that can be utilized to assess patients prior to utilizing the neuropsychological 
tests.  
In this pilot study QOL was also examined. This study showed that women with breast 
cancer reported a lower QOL (global quality of life), which is congruent with previous studies 
(Ahles, 2012; Hess & Insel, 2007; Miura, Ando, and Imani, 2016; Myers, Wick, & Kelpm, 
2015; Von Ah D et al., 2013; Vitali et al., 2017). However, with this single-item measure for 
QOL (LASA) there was no significant difference between the groups. Upon further analysis 
between QOL and symptom burden (MSAS-SF, PROMIS Anxiety 6a, and Depression 6a) 
higher QOL was associated with low levels of anxiety, depression, and symptom burden in 
both healthy controls and women with breast cancer. However, the women with breast cancer 
demonstrated significantly more anxiety than healthy controls and were significantly more 
depressed. Women with breast cancer also reported more symptoms than the healthy controls. 
The healthy controls reported seven symptoms, while the women with breast cancer reported 
22 symptoms.  
 MSAS-SF was used to assess symptom burden. The results were consistent with 
previous studies (Cheng, Wong, and Koh, 2016; Weber and Davies, 2011) showing that lack of 
energy, difficulty sleeping, worrying, pain, hair loss, and difficulty concentrating were the most 
commonly reported by cancer patients. The women with breast cancer group also reported 
several more symptoms as bothersome over the past week compared to the healthy control 




was frequently reported in women with breast cancer.  Also, difficulty sleeping, pain and 
worrying were the highest reported symptoms for both groups but more common for women 
with breast cancer. These symptoms could be higher in the women with breast cancer due to the 
treatment, but further studies are needed to confirm this relationship. These findings correspond 
to previous studies that suggested that women with breast cancer may experience multiple 
symptoms that may or may not be associated with the development of cognitive impairment 
(Cheng, Wong, and Koh, 2016; Cutshall et al., 2015; Wagland et al., 2015).  
Limitations 
 
The first limitation was the small sample size (N=40). In addition, the sample 
population had variability regarding endocrine therapy and chemotherapy agents used in their 
treatment regimens. The second limitation was the feasibility of recruiting subjects. This 
researcher encountered difficulties in recruitment for the following reasons: medical 
oncologists decreased clinic hours, nurse navigator who identified potential participants went 
out on leave of absence, and patients missing or cancelling clinical visits.  In future studies, the 
researcher should incorporate the office scheduling personnel to ask the patient when 
confirming the appointment if the potential participant could come 30 minutes earlier to 
participate in this study. The third limitation was the differences in race and education between 
the groups: women with breast cancer and healthy controls. Most healthy controls were white 
(65%) more highly educated while the women with breast cancer who were predominately 
black (75%) and less educated. Previous mentioned studies found that race, age, and fewer 
years of education (Visovatti et al., 2016) had significant associations with cognitive 
impairment. The fourth limitation of the study was due to the time subjects spent completing 




while others took 40 minutes or longer to complete. When the tools were administered to the 
women with breast cancer, the majority found that completing the Symptom burden scale 
(MSAS-SF) was difficult due to the large number of symptoms on the instrument.  The final 
limitations was that this study used a convenience sample, was not longitudinal, had many 
variations of chemotherapy regimens received, and the inconsistency of length of time on ET 
therapy.  Further, there were no baseline assessments for the women with breast cancer to 
determine if there was a change in cognitive function before breast cancer treatment.  
Future research 
 
This study utilized two different methods when recruiting participants which included 
the ECU email list server and utilization of a nurse navigator that screened breast cancer 
potential participants. The ECU email list server was excellent means of obtaining participants. 
However, by using the ECU email list server, the resulting healthy control group had a higher 
educational level then the women with breast cancer group. In the future, a different list serve 
that was more reflective of the general community might result in a greater congruence with the 
typical breast cancer patient treated in this university clinic. Attempts to find subjects more 
closely matched regarding education status, ethnicity, and age would need to be taken. In future 
studies, enlisting women with breast cancer group prior to obtaining healthy controls might 
result in a sample that is more reflective of the breast cancer patients.   
In addition to the demographics, treatment protocols for the women with breast cancer 
need to be evaluated. Due to the small sample size, comparison of treatment protocols could not 
be assessed. During recruitment it was difficult to obtain participants who did not receive 
chemotherapy, so future studies should utilize multiple clinics for recruitment. This study was 




treatment protocols prior to conducting the next study would be to have a chart review pulled 
from all women with breast cancer who received treatment. This would give a firm 
understanding of the types of treatment protocols used, in addition to the age and ethnicity of 
the potential participants.  
The tools for CI were easy to administer but a larger sample is needed to determine if 
these are useful as a screening tool for cognitive impairment.  It took the participants on 
average 30-40 minutes to complete all of the survey instruments. Utilizing shorter instrument 
tools to reduce the time it took to complete would need to be considered for future studies. The 
PROMIS Anxiety and Depression tools can be streamlined from a six item tool down to three 
items. The MSAS-SF, when administered was complicated and time consuming with the 
number of symptoms evaluated, future studies should focus on previous symptoms noted to be 
involved with women with breast cancer, which could help to eliminate several symptoms. This 
study could be used as a reference to assess which symptoms were not bothersome to the 
women with breast cancer. Both groups also expressed confusion when filling out the EMQ, 
they expressed concerns with how to code responses, which could have led to the mixed results. 
Future studies would need to evaluate and look at alternative tools that assess memory.  
This study found that for two of the three cognitive function self-reported tools, there 
were significant differences between groups. Illustrating the need to reproduce this study with a 
larger to determine if these measures continue to demonstrate differences between healthy 
controls and breast cancer patients. Additionally, another study could be conducted to test the 
utility of these measures as screening instruments. Subjects in the proposed study would all be 
screened and then receive a battery of psychologist administered tests for CI to determine if 




of study could be utilized to determine if there is a cut-off scores that indicate a need for further 
neurological testing.   
This study also suggests that greater number of symptoms are associated with increased 
CI impairment, so a larger sample of subjects would be needed to confirm the relationship 
between symptom burden and CI. Also, the next study should be proposed as a longitudinal 
study instead of a cross-sectional study so we can measure these CI impairment tools over a 
course of time and compare the results throughout the patient’s treatment. 
Conclusion 
 
 This study evaluated three-self reported tools on cognition (attention, memory, and 
executive function) in conjunction with self-reported tools on symptom burden, QOL, anxiety, 
and depression. The findings of this study corresponded with findings from previous studies. 
However, a larger scale study with a larger sample size needs to be completed to validate these 
findings. In addition, scheduling time with potential participants so they are not rushed and 
come prepared to complete the survey. Many women found that due to the large number of 
surveys, it seemed overwhelming at times, since it took most of the participants 30 minutes or 
longer to complete. Women with breast cancer did report more symptoms than the controls 
group further warranting additional studies on a larger scale. This study did show that women 
with breast cancer are experiencing more symptoms and at more severe rating, but with this 
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APPENDIX B:  STAGING OF BREAST CANCER 
Stage TMN Explanation 
Stage 0  
 
This is ductal carcinoma in situ (DCIS), the earliest 
form of breast cancer. In DCIS, cancer cells are still 
within a duct and have not invaded deeper into the 
surrounding fatty breast tissue. 
Lobular carcinoma in situ (LCIS) sometimes also is 
classified as stage 0 breast cancer, but most 
oncologists believe it is not a true cancer or pre-cancer. 
 
*In all cases the cancer has not spread to lymph nodes 
or distant sites. 
Stage IA  T1, N0, M0 The tumor is 2 cm (about 3/4 of an inch) or less across 
(T1) and has not spread to lymph nodes (N0) or distant 
sites (M0). 
Stage IB  T0 or T1, 
N1mi, M0 
The tumor is 2 cm or less across (or is not found) (T0 
or T1) with micrometastases in 1 to 3 axillary lymph 
nodes (the cancer in the underarm lymph nodes is 
greater than 0.2mm across and/or more than 200 cells 
but is not larger than 2 mm)(N1mi).  
*The cancer has not spread to distant sites (M0). 
Stage IIA T0 or T1, N1 
(but not 
N1mi), M0: 
The tumor is 2 cm or less across (or is not found) (T1 
or T0) and either: 
It has spread to 1 to 3 axillary (underarm) lymph 
nodes, with the cancer in the lymph nodes larger than 
2 mm across (N1a), 
OR 
Tiny amounts of cancer are found in internal 
mammary lymph nodes (nodes near the breast bone) 
on sentinel lymph node biopsy (N1b), 
OR 
It has spread to 1 to 3 axillary lymph nodes and to 
internal mammary lymph nodes (found on sentinel 
lymph node biopsy) (N1c). 





T2, N0, M0 The tumor is larger than 2 cm but less than 5 cm 
(about 2 inches) across (T2) but hasn't spread to the 
lymph nodes (N0). The cancer has not spread to distant 
sites (M0). 
Stage IIB T2, N1, M0 The tumor is larger than 2 cm but less than 5 cm across 
(T2). It has spread to 1 to 3 axillary lymph nodes 
and/or tiny amounts of cancer are found in internal 
mammary lymph nodes on sentinel lymph node biopsy 
(N1). The cancer hasn't spread to distant sites (M0). 
OR 
T3, N0, M0 The tumor is larger than 5 cm across but does not grow 
into the chest wall or skin (T3). The cancer has not 
spread to the lymph nodes (N0) or to distant sites 
(M0). 
Stage IIIA T0 to T2, N2, 
M0 
The tumor is not more than 5 cm across (or cannot be 
found) (T0 to T2). It has spread to 4 to 9 axillary 
lymph nodes, or it has enlarged the internal mammary 
lymph nodes (N2). The cancer hasn't spread to distant 
sites (M0). 
OR 
T3, N1 or N2, 
M0 
The tumor is larger than 5 cm across but does not grow 
into the chest wall or skin (T3). It has spread to 1 to 9 
axillary nodes, or to internal mammary nodes (N1 or 
N2). The cancer hasn't spread to distant sites (M0). 
Stage IIIB T4, N0 to N2, 
M0 
The tumor has grown into the chest wall or skin (T4), 
and one of the following applies: 
• It has not spread to the lymph nodes (N0). 
• It has spread to 1 to 3 axillary lymph nodes 
and/or tiny amounts of cancer are found in 
internal mammary lymph nodes on sentinel 




• It has spread to 4 to 9 axillary lymph nodes, or 
it has enlarged the internal mammary lymph 
nodes (N2). 
The cancer hasn't spread to distant sites (M0). 
Inflammatory breast cancer is classified as T4d and 
is at least stage IIIB. If it has spread to many nearby 
lymph nodes (N3) it could be stage IIIC, and if it has 
spread to distant lymph nodes or organs (M1) it would 
be stage IV. 
Stage IIIC any T, N3, M0 The tumor is any size (or can't be found), and one of 
the following applies: 
• Cancer has spread to 10 or more axillary lymph 
nodes (N3). 
• Cancer has spread to the lymph nodes under 
the collar bone (infraclavicular nodes) (N3). 
• Cancer has spread to the lymph nodes above 
the collar bone (supraclavicular nodes) (N3). 
• Cancer involves axillary lymph nodes and has 
enlarged the internal mammary lymph nodes 
(N3). 
• Cancer has spread to 4 or more axillary lymph 
nodes, and tiny amounts of cancer are found in 
internal mammary lymph nodes on sentinel 
lymph node biopsy (N3). 
The cancer hasn't spread to distant sites (M0). 
Stage IV any T, any N, 
M1 
The cancer can be any size (any T) and may or may 
not have spread to nearby lymph nodes (any N). It has 
spread to distant organs or to lymph nodes far from the 
breast (M1). The most common sites of spread are the 
bones, liver, brain, or lungs. 






APPENDIX C:  DEMOGRAPHIC TOOL 
 
 ID Number:___________   
1. Date of diagnosis with breast cancer? ____  
2. Age today? ___  
3. Marital status?  
___single  
___ married  
___ divorced  
___ widowed  
___ in a relationship   
4. Ethnicity?  
 ___ White, non-Hispanic   ___ Native Hawaiian/Pacific Islander  
 ___ Black, non-Hispanic   ___ Two or more races, non-Hispanic  
 ___ American Indian   ___ Hispanic/Latino  
 ___ Asian    ___ Other (please describe)  
5. Highest level of education?  
 ___ grade school  
 ___ high school  
 ___ college  
 ___ graduate school 
7. Smoker? Y or N 
8. Height______ Weight__________ 
9. List of current medications  (leave out for health controls) 








I.  At this time, how well do you feel you are functioning in each of the areas below? 
Circle the number that best describes how you are doing in each area at present. 
 
1. Getting started on activities (tasks, jobs) you intend to do 
     Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
2. Planning your daily activities. 
     Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
3. Following through on your plans. 
    Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
4. Doing things that take time and effort. 
    Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
5. Making your mind up about things.  
Not at all                    Extremely well 








6. Finishing things you have started. 
    Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
7. Keeping your mind on what you are doing. 
     Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
8. Remembering to do all thing things you started out to do. 
      Not at all                   Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
9. Keeping track of what you are saying or doing (keeping your train of thought). 
     Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
10. Keeping your mind on what others are saying. 
     Not at all                Extremely well 
  0 1 2 3 4 5 6 7 8 9 10 
 
11. Keeping yourself from saying or doing things you did not want to say or do. 
       Not at all                 Extremely well 
   0 1 2 3 4 5 6 7 8 9 10 
 
12. Being patient with others. 
  Not at all                  Extremely  











13. How hard you find it to concentrate on details. 
       Not at all                   A great deal    
  0 1 2 3 4 5 6 7 8 9 10 
 
14. How often you make mistakes on what you are doing. 
       Not at all                  A great deal    
  0 1 2 3 4 5 6 7 8 9 10 
 
15. Forgetting to do important things. 
       Not at all                  A great deal    
  0 1 2 3 4 5 6 7 8 9 10 
 
16. Getting easily annoyed or irritated. 
       Not at all                  A great deal    





APPENDIX E:  EVERYDAY MEMORY QUESTIONNAIRE 
 
Everyday Memory Questionnaire - Revised 
Instructions Below are listed some examples of things that happen to people in everyday life.  
Some of them may happen frequently and some may happen very rarely.  We would like to know 
how often on average you think each one has happened to you over the past month.  Write the 
appropriate number in the box beside the item.  
  
0. Once or less in the last month. 1. More than once a month but less than once a week. 2. About 
once a week. 3. More that once a week but less than once a day. 4. Once or more in a day.  
  
1. Having to check whether you have done something that you should have done.  
  
2. Forgetting when it was that something happened; for example, whether it was yesterday or last 
week.  
  
3. Forgetting that you were told something yesterday or a few days ago, and maybe having to be 
reminded about it.  
  
4. Starting to read something (a book or an article in a newspaper, or a magazine) without 
realizing you have already read it before.  
  
5. Finding that a word is “on the tip of your tongue”. You know what it is but cannot quite find 
it.  
  
6. Completely forgetting to do things you said you would do, and things you planned to do.  
  
7. Forgetting important details of what you did or what happened to you the day before.  
  
8. When talking to someone, forgetting what you have just said.  Maybe saying “what was I 





9. When reading a newspaper or magazine, being unable to follow the thread of a story  
  
10. Forgetting to tell somebody something important, perhaps forgetting to pass on a message or 
remind someone of something.  
  
11. Getting the details of what someone told you mixed up and confused.  
  
12. Forgetting where things are normally kept; or looking for them in the wrong place.  
  















one box per 
row. In the 
past 7 days…  
Never  Rarely (once)  Sometimes (2-3 
times)  
Often (once a 
day)  
Very often 
(several times a 
day)  
































NQCOG77r1  I had to 
work really 


















































Y do you 
currently 
have…  
None  A little  Somewhat  A lot  Cannot do  
























nts that are 
























NQCOG25r1  Managing 
your time 



















































APPENDIX I:  PROMIS ANXIETY 6A 
 
 Please respond 
to each question 
or statement by 
marking one 
box per row. In 
the past 7 
days…  
Never  Rarely  Sometimes  Often  Always  














EDANX40  I found it hard 












































































APPENDIX J:  PROMIS DEPRESSION 6A 
 
 Please respond 
to each question 
or statement by 
marking one 
box per row. In 
the past 7 
days...  
Never  Rarely  Sometimes  Often  Always  






































































EDDEP36  I felt 
unhappy.........
.......................
.............  
 
1  
 
2  
 
3  
 
4  
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